Annamari Vuorela

Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial

Karim Fizazi, Christophe Massard, Petri Bono et al. · The Lancet Oncology · 2014 · 194 citations · Full text

Medicine, Oncology, Urology +13

Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans.

Tom Wikberg, Annamari Vuorela, Pekka Ottoila et al. · Drug Metabolism and Disposition · 1993 · 89 citations

Life Sciences, Biochemistry, Pharmacology +16

Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study

Christophe Massard, Heidi Penttinen, Egils Vjaters et al. · European Urology · 2015 · 61 citations · Full text

Medicine, Oncology, Pharmacology +17

The effect of an increased ratio of carbidopa to levodopa on the pharmacokinetics of levodopa

Seppo Kaakkola, Pekka T. Männistö, Erkki Nissinen et al. · Acta Neurologica Scandinavica · 2009 · 36 citations

Medicine, Clinical Pharmacokinetics, Pharmacology +13

First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis

Mari Karimaa, Reetta Riikonen, Henna Kettunen et al. · Molecular Cancer Therapeutics · 2022 · 24 citations · Full text

Medicine, Oncology, Pharmacology +17